Atherosclerosis in chronic kidney disease: lessons learned from glycation in diabetes.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 22391251.
- Also identified by DOI 10.1016/j.mcna.2011.11.005.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
In diabetes, glycation is a nonenzymatic posttranslational modification resulting from the bonding of a sugar molecule with a protein or lipid followed by oxidation, resulting in the development of advanced glycation end products (AGE). Like glycation, carbamylation is a posttranslational protein modification that is associated with AGE formation. Glycation of extracellular matrix proteins and low-density lipoprotein with subsequent deposition in the vessel wall could contribute to inflammatory response and atheroma formation. It is logical to extrapolate that carbamylation may result in modification of vessel wall proteins similar to glycation, and predispose to atherosclerosis.
Medical subject headings
- Atherosclerosis
- Diabetes Complications
- Glycation End Products, Advanced
- Kidney Diseases
- Lipoproteins, LDL
- Plaque, Atherosclerotic